Perioperative Durvalumab Plus Chemo Yields Responses, EFS Benefit in Resectable NSCLC
September 11, 2023Kyle DohertyThe addition of perioperative durvalumab to neoadjuvant chemotherapy led to a significant improvement in terms of pathological complete response and event-free survival c
Updated on: October 11,2023
24
Perioperative Durvalumab Plus Chemo Yields Responses, EFS Benefit in Resectable NSCLC
September 11, 2023Kyle DohertyThe addition of perioperative durvalumab to neoadjuvant chemotherapy led to a significant improvement in terms of pathological complete response and event-free survival c
Updated on:October 11,2023
24
